Clinical trials: Moderate to Severe Asthma
Moderate to Severe Allergic Asthma
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently…
- Trial name
- NCT01673672
- Testing
- CYT003
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 365 people
- Sponsor
- Cytos Biotechnology AG
Asthma
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
- Trial name
- NCT02219048
- Testing
- PF-03715455
- Where
- 28 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pfizer
Asthma
Asthma and Quantifying Delivery Of Radio Labeled Aerosol
Introduction: Inhalation therapy has been established as an efficient route to treat asthma exacerbations, but coupled to noninvasive ventilation (NIV) remains quite challenging.
- Trial name
- NCT01823926
- Testing
- Noninvasive ventilation, Jet nebulizer, The vibrating mesh nebulizer (VMN)
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- Universidade Federal de Pernambuco
Allergic Asthma
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma
The combined treatment of anti-IgE monoclonal antibody and standardized allergen immunotherapy has good efficacy and safety in allergic diseases.
- Trial name
- NCT06771934
- Testing
- Allergen-specific immunotherapy(AIT), omalizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qianfoshan Hospital
Moderate to Severe Asthma
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
Purpose: This study aims to improve asthma care by helping clinicians at community health centers prescribe a guideline-recommended treatment called SMART (Single Maintenance and Reliever Therapy).
- Trial name
- CHEST (NCT07241117)
- Testing
- Implementation bundle
- Where
- 7 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Washington University School of Medicine
Asthma
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
- Trial name
- NCT01854047
- Testing
- Dupilumab, ICS/LABA therapy, Salbutamol/albuterol
- Where
- 201 sites in United States, Argentina and 14 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05186909
- Testing
- CM310
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Keymed Biosciences Co.Ltd
Asthma
Effect of Spacer in Extrafine Formoterol-Beclomethasone Treatment to Asthma
Combined inhaled treatment with long acting adrenergics and steroids in an unique inhaler plays an important role in the management of non-mild asthma.
- Trial name
- NCT00850265
- Testing
- Volumatic spacer
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital General de Requena
Asthma
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.
- Trial name
- NCT07436221
- Testing
- AK139
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Akeso
Moderate to Severe Asthma
A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe…
- Trial name
- NCT07372287
- Testing
- CM326
- Where
- China
- Volunteers
- 230 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Allergic Asthma
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
The primary objective is to assess the clinical effectiveness of long-term omalizumab therapy in 240 patients treated over an 8 year period in a real-life clinical setting and to compare the pre- and post-treatment clinical…
- Trial name
- The Reality (NCT01776177)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Joseph D. Diaz, MD
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Bronchial Asthma
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
- Trial name
- NCT07054034
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Moderate to Severe Asthma
PULmonary Stimulation for Asthma Relief
This study aims to assess the safety and efficacy of Pulmonary Neuromodulation in patients suffering from moderate to severe asthma
- Trial name
- PULSAR (NCT07709754)
- Testing
- Spinal Cord Stimulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Spiro Medical, Inc.
Asthma
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
- Trial name
- NCT06376045
- Testing
- Rocatinlimab
- Where
- 154 sites in United States, Argentina and 17 more
- Volunteers
- 317 people
- Sponsor
- Amgen